Efgartigimod
Efgartigimod is a humanized IgG1 Fc fragment that binds to the neonatal Fc receptor and inhibits its interaction with IgG, thereby reducing IgG recycling and increasing degradation of IgG and pathological autoantibodies, without altering other immunoglobulins and albumin levels.
Enroll in this clinical study
How is Efgartigimod being studied in lupus nephritis?
The efficacy and safety of Efgartigimod in Chinese patients with active lupus nephritis is being studied in this Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Proof-of-Concept Study. The primary endpoint is the change from baseline to week 24 in urine protein creatinine ratio. The secondary endpoints include the proportion of patients achieving complete and partial renal response at 24 weeks.
Eligibility Criteria
Aged ≥18 years
Active, proliferative LN Class III or IV [excluding Class III (C), IV-S (C), and IV-G (C)], either with or without the presence of Class V using the 2003 International Society of Nephrology (ISN)/Renal Pathology Society (RPS)
Require LN induction therapy (glucocorticoids and MMF/MPA) based on the investigator's clinical judgment.